Inify Laboratories - mandatory notification of trade

Stockholm, Sweden, August 29, 2025; Inify Laboratories AB (publ.) has been notified that the following transactions have been completed by a primary insider in Inify; Martin Ingvar, board member and primary insider in Inify, has acquired 9,500 shares in Inify at an average price of SEK 5.50 per share on August 28th. After the transaction, Ingvar holds 186,063 shares. This information is subject to the disclosure requirements pursuant to the EU Market Abuse Regulation (EU 596/2014 article 19) and section 5-12 of the Norwegian Securities Trading Act. For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com. ### About Inify Laboratories The future of pathology Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. It uses a fully digital, standardized and AI- supported workflow to optimize quality and response times, initially within prostate.The concept is scalable and can be extended to other diagnoses. The service includes the whole chain of sample handling: from logistics, to sample preparation, to reporting by a pathologist. The report is assisted by our own AI, proven in clinical studies to have world-leading accuracy. The complete workflow is supported by a tailor-made process control system. The company, based in Sweden, became independent in 2022 through a spin-off fromContextVision (https://www.contextvision.com/), with 40 years of experience within digital imaging for medical applications. Its' share is listed onEuronext Growth Oslo under the ticker INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).